These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24719188)

  • 1. Periostin is a new potential prognostic biomarker for glioma.
    Tian B; Zhang Y; Zhang J
    Tumour Biol; 2014 Jun; 35(6):5877-83. PubMed ID: 24719188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic reg IV is a novel prognostic marker for glioma patient survival.
    Wang Q; Deng J; Yuan J; Wang L; Zhao Z; He S; Zhang Y; Tu Y
    Diagn Pathol; 2012 Jun; 7():69. PubMed ID: 22713481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients.
    Tseng JY; Yang CY; Yang SH; Lin JK; Lin CH; Jiang JK
    J Surg Res; 2015 Dec; 199(2):362-70. PubMed ID: 26119272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of periostin in the liver metastasis of colorectal cancer.
    Wu G; Wang X; Zhang X
    Cancer Biother Radiopharm; 2013 May; 28(4):298-302. PubMed ID: 23347152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
    Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin is a novel therapeutic target that predicts and regulates glioma malignancy.
    Mikheev AM; Mikheeva SA; Trister AD; Tokita MJ; Emerson SN; Parada CA; Born DE; Carnemolla B; Frankel S; Kim DH; Oxford RG; Kosai Y; Tozer-Fink KR; Manning TC; Silber JR; Rostomily RC
    Neuro Oncol; 2015 Mar; 17(3):372-82. PubMed ID: 25140038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
    Jiang S; Pei L; Yang ZL; Liu G
    Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma.
    Ma J; Lang B; Wang X; Wang L; Dong Y; Hu H
    J Clin Neurosci; 2014 Nov; 21(11):1885-90. PubMed ID: 25001988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMP4, a new prognostic factor for glioma.
    Wu Q; Yao J
    World J Surg Oncol; 2013 Oct; 11():264. PubMed ID: 24099560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and prognostic value of JAM-A in gliomas.
    Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
    J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma.
    Chen X; Ma WY; Xu SC; Liang Y; Fu YB; Pang B; Xin T; Fan HT; Zhang R; Luo JG; Kang WQ; Wang M; Pang Q
    J Neurooncol; 2014 Aug; 119(1):39-47. PubMed ID: 24906438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma.
    Yu JW; Zhang P; Wu JG; Wu SH; Li XQ; Wang ST; Lu RQ; Ni XC; Jiang BJ
    J Exp Clin Cancer Res; 2010 Nov; 29(1):141. PubMed ID: 21054902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
    Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
    Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic expression of BAP1 as an independent prognostic biomarker for patients with gliomas.
    Zhang XK; Xi SY; Sai K; Chen HD; Zhong ZH; Wu QL; Zeng J
    Int J Clin Exp Pathol; 2015; 8(5):5035-43. PubMed ID: 26191197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    Wu X; Wu F; Xu D; Zhang T
    J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma.
    Wang L; He S; Tu Y; Ji P; Zong J; Zhang J; Feng F; Zhao J; Gao G; Zhang Y
    J Clin Neurosci; 2013 Jul; 20(7):958-63. PubMed ID: 23707602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.